STTK Stock Overview
A clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Shattuck Labs, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.59 |
52 Week High | US$11.76 |
52 Week Low | US$1.33 |
Beta | 1.75 |
11 Month Change | -9.80% |
3 Month Change | -51.36% |
1 Year Change | 59.56% |
33 Year Change | -83.12% |
5 Year Change | n/a |
Change since IPO | -81.45% |
Recent News & Updates
Recent updates
Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
Jun 15Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?
Jun 28We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Mar 09Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?
Nov 23Shattuck Labs GAAP EPS of -$0.65 misses by $0.06
Aug 11We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Jul 26Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 18Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
Feb 25Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?
Nov 23We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth
Aug 24Shattuck Labs names Abhinav Shukla as chief technical officer
Jun 01Shattuck Labs EPS beats by $0.11, beats on revenue
May 10Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
May 07Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?
Mar 08We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely
Jan 12Shattuck Labs reports Q3 results
Nov 13Shareholder Returns
STTK | US Biotechs | US Market | |
---|---|---|---|
7D | 2.6% | 0.1% | 0.06% |
1Y | 59.6% | 13.8% | 22.6% |
Return vs Industry: STTK exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: STTK exceeded the US Market which returned 22.2% over the past year.
Price Volatility
STTK volatility | |
---|---|
STTK Average Weekly Movement | 12.5% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STTK's share price has been volatile over the past 3 months.
Volatility Over Time: STTK's weekly volatility has decreased from 23% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 75 | Taylor Schreiber | www.shattucklabs.com |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc. Fundamentals Summary
STTK fundamental statistics | |
---|---|
Market cap | US$166.57m |
Earnings (TTM) | -US$85.28m |
Revenue (TTM) | US$4.12m |
41.5x
P/S Ratio-2.0x
P/E RatioIs STTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
STTK income statement (TTM) | |
---|---|
Revenue | US$4.12m |
Cost of Revenue | US$74.64m |
Gross Profit | -US$70.52m |
Other Expenses | US$14.77m |
Earnings | -US$85.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.79 |
Gross Margin | -1,709.92% |
Net Profit Margin | -2,067.99% |
Debt/Equity Ratio | 0% |
How did STTK perform over the long term?
See historical performance and comparison